Shire

Shire’s Angus Russell to retire in 2013, Ornskov to succeed as CEO

Friday, October 26, 2012 12:07 PM

The board of directors of Shire, a global specialty biopharmaceutical company based in Ireland, has announced the retirement in 2013 of chief executive Angus Russell after 13 years with the company and 32 years in the pharmaceutical industry.

More... »

AMRI, Shire ink 5-year extension of API supply agreement

Monday, October 22, 2012 12:22 PM

AMRI, a global contract research and manufacturing organization, has entered into a multi-year supply agreement for an undisclosed product with Shire U.S. Manufacturing, a subsidiary of specialty biopharmaceutical company Shire.

More... »

Y-Prime names Greef as senior business analyst

Thursday, August 30, 2012 02:53 PM

Y-Prime Technologies, an Malvern, Penn.-based eClinical products and life sciences consulting services company, has expanded its international operations in Europe and has named Jeanette Anne Greef as senior business analyst in the U.K. office.

More... »

Shire joins ABPI

Tuesday, August 21, 2012 09:56 AM

Specialty biopharmaceutical company Shire has joined the Association of the British Pharmaceutical Industry (ABPI) as a full member.

More... »

PharmaNet/i3 names VP and general manager, neuroscience

Monday, July 16, 2012 11:05 AM

PharmaNet/i3, inVentiv Health’s clinical segment, has appointed Robert Lasser, M.D., MBA, vice president and general manager, neuroscience, overseeing the management of all clinical projects handled by PharmaNet/i3’s neuroscience group and the Rater Training Services team. Dr. Lasser will be based in Princeton, N.J.

More... »

Shire’s VPRIV shows significant improvement in Gaucher-related bone disease

Friday, June 29, 2012 12:38 PM

Shire, a global specialty biopharmaceutical company based in Dublin, released new data that show VPRIV (velaglucerase alfa for injection), the company’s enzyme replacement therapy for type 1 Gaucher disease, significantly improved selected markers of Gaucher-related bone disease in patients.

More... »

Report: Orphan drug market on the rise

Thursday, May 24, 2012 09:00 AM

GBI Research, a pharmaceutical market expert, has released its report "Orphan Disease Therapeutics Market to 2018: Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation,” which provides insights into the orphan disease therapeutics market until 2018.

More... »

Promedior names Suzanne L. Bruhn president and CEO

Wednesday, May 16, 2012 10:08 AM

Promedior, a Malvern, Penn.-based clinical stage biotech developing novel biologic therapeutics for the treatment of fibrosis, has appointed Suzanne L. Bruhn, Ph.D., as president, CEO and to the board of directors.

More... »

Shire acquires Pervasis’ assets

Monday, April 16, 2012 09:47 AM

Shire Pharmaceuticals, a global specialty biopharmaceutical company, will acquire all the assets of Pervasis Therapeutics of Cambridge, Mass.

More... »

Shire to license CNS disorder drug worldwide

Wednesday, March 21, 2012 10:36 AM

Heptares Therapeutics, a U.K.-based drug discovery company, has granted Shire Pharmaceuticals, the global specialty biopharmaceutical company, exclusive worldwide license of novel adenosine A2A antagonist for central nervous system disorders, currently in preclinical development.

More... »